Thalidomide-O-amido-C8-NH2 hydrochloride

Background Introduction

Thalidomide-O-amido-C8-NH2 hydrochloride is a specialized E3 ligase ligand-linker conjugate designed for use in targeted protein degradation technologies. As a derivative of thalidomide, this compound leverages the unique binding capabilities of thalidomide to recruit cereblon (CRBN), an E3 ubiquitin ligase, a critical component in PROTAC (Proteolysis Targeting Chimera) development. The structure incorporates an O-amido-C8 alkyl linker that terminates with a primary amine group (NH2), enabling efficient conjugation to various target ligands for custom synthesis of PROTAC molecules.

Mechanism

The mechanism of Thalidomide-O-amido-C8-NH2 hydrochloride centers on its ability to facilitate targeted protein degradation via the ubiquitin-proteasome system. As part of a bifunctional PROTAC molecule, the thalidomide moiety binds selectively to the E3 ligase cereblon (CRBN), while the C8 amido linker provides spatial flexibility and a reactive amine group for attachment to a specific ligand targeting the protein of interest. When assembled into a PROTAC, this conjugate effectively brings the E3 ligase and the target protein into close proximity, promoting ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Thalidomide-O-amido-C8-NH2 hydrochloride is widely employed in the synthesis of PROTACs for both research and drug discovery applications. Its versatile linker design allows for the generation of various PROTACs targeting specific disease-related proteins, including oncogenic kinases, transcription factors, and epigenetic regulators. This conjugate is essential for scientists developing new therapeutic strategies in oncology, neurodegeneration, and autoimmune diseases, where selective protein knockdown is desired. Additionally, it serves as a key intermediate in the creation of customized degrader libraries for high-throughput screening and target validation studies.

Thalidomide-O-amido-C8-NH2 hydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in the development of PROTACs, facilitating targeted protein degradation by linking a thalidomide-based ligand with a flexible linker. The following provides a detailed description of this molecule's linker, ligand, and reactive site, along with recommended target protein ligands for optimal application.

Linker: The linker in this molecule is an eight-carbon chain, providing moderate length that balances flexibility and rigidity. It is an aliphatic type, which ensures adequate spacing between ligand and target, and it is non-cleavable, promoting stable conjugation.

Ligand: The ligand is derived from thalidomide, a well-characterized E3 ligase modulator. Its structural characteristics include a glutarimide moiety, which is crucial for binding to the cereblon E3 ligase, enhancing the specificity and efficiency of the PROTAC.

Reactive Site: The reactive site features an amido group, which is designed to couple efficiently with amine or hydroxyl groups on the target protein ligand. Recommended reaction types include amide bond formation, which is reliable for stable conjugation in aqueous environments.

Recommended Target Protein Ligand: The molecule is compatible with electrophilic warheads such as acrylamides, which target cysteine residues on proteins. This compatibility provides advantages in terms of selectivity and potency, making it ideal for applications in studying proteins with accessible cysteine sites, thereby enabling precise modulation of protein function in cellular environments.